Marcie A. Goldstein

Davis Polk advised the underwriters in connection with a $202.5 million public offering of common stock by Turning Point Therapeutics, Inc. Turning Point Therapeutics’ common stock is…

Davis Polk advised the sole bookrunner in connection with the SEC-registered offering of 2,329,000 shares of Class A common stock of Appian Corporation by Appian and certain existing…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…

Davis Polk advised the underwriters on the SEC-registered initial public offering by 9F Inc. of 8,900,000 American Depositary Shares, consisting of 6,750,000 ADSs sold by 9F and 2,150,000…

Davis Polk advised the sole bookrunner in connection with the $168 million SEC-registered secondary offering of 12,000,000 shares of Class A common stock of Hostess Brands, Inc. by certain…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $110 million initial public offering of 7,857,145 shares of common stock by…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an $86.25 million public offering of common stock of Forty Seven, …

Davis Polk advised the underwriter in connection with a secondary offering of 12,000,000 American Depositary Shares of Hutchison China Meditech Limited (“Chi-Med”), each representing five…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the SEC-registered offering by Fiserv, Inc. of €500 million principal amount of…

Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq…